Oxford BioMedica (LSE:OXB) Research & Development: £5.1 Mil (TTM As of Dec. 2025)


LSE:OXB Oxford BioMedica PLC LSE:OXB
68 GF Score
Price £6.34
GF Value £5.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Research & Development?

Oxford BioMedica LSE:OXB +3.26% 68 Research & Development is £5.1 Mil as of Dec. 2025. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.36 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Oxford BioMedica's Research & Development for the six months ended in Dec. 2025 was £3.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £5.1 Mil.

Oxford BioMedica  (LSE:OXB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Oxford BioMedica Research & Development Related Terms

Oxford BioMedica Research & Development Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Research & Development Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.19 60.94 11.47 4.54 5.06

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.95 2.25 2.29 1.98 3.08
LSE:OXB
68GF Score
Oxford BioMedica PLC LSE:OXB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £5.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £5.1 Mil mean?
Oxford BioMedica (LSE:OXB) has a Research & Development of £5.1 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Oxford BioMedica and its competitors.
Is Oxford BioMedica's Research & Development too high?
Oxford BioMedica's current Research & Development is £5.1 Mil. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Research & Development compare to VRTX and REGN?
Oxford BioMedica's Research & Development of £5.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current Research & Development is £5.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.34 — trading 18.3% above its estimated fair value. The current Research & Development is £5.1 Mil. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current Research & Development is £5.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.34 is trading 18.3% above its estimated GF Value™ of £5.36. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for LSE:OXB:

  • Research & Development: £5.1 Mil
  • GF Value™: £5.36 vs. price of £6.34 (18.3% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXBl:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score

Get the complete analysis for LSE:OXB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.34
Price
£5.36
GF Value